We are live on ! Find out more
XBIT icon

XBiotech
XBIT

48 hedge funds and large institutions have $7.81M invested in XBiotech in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.58% less ownership

Funds ownership: 11.2% → 9.63% (-1.6%)

9% less funds holding

Funds holding: 53 → 48 (-5)

23% less capital invested

Capital invested by funds: $10.1M → $7.81M (-$2.34M)

50% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 22

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $3K

Holders
48
Holders Change
-5
Holders Change %
-9.43%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
22
Closed
9
Calls
–
Puts
$3K
Net Calls
-$3K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$106K
2
Jane Street
Jane Street
New York
+$90.2K
3
Bank of America
Bank of America
North Carolina
+$86.4K
4
HF
HRT Financial
New York
+$77.5K
5
Squarepoint
Squarepoint
New York
+$66.3K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$400K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$374K
3
Goldman Sachs
Goldman Sachs
New York
-$258K
4
BlackRock
BlackRock
New York
-$211K
5
YIH
Y-Intercept (HK)
Hong Kong
-$142K
Name Holding Trade Value Shares
Change 		Change in
Stake
TNB
26
Thomasville National Bank
Georgia
$35.5K – – –
SF
27
Synovus Financial
Georgia
$31.4K – – –
PAS
28
Point72 Asia (Singapore)
Singapore
$18.1K -$20.5K -6,908 -50%
UBS Group
29
UBS Group
Switzerland
$17.2K +$4.24K +1,432 +28%
CSS
30
Cubist Systematic Strategies
Connecticut
$14.2K -$61K -20,597 -79%
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$8K +$1.09K +368 +15%
JP Morgan Chase
32
JP Morgan Chase
New York
$6.34K -$19.2K -6,499 -73%
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$2.47K – – –
ME
34
McIlrath & Eck
Washington
$2K – – –
Jones Financial Companies
35
Jones Financial Companies
Missouri
$999 – – –
Fidelity Investments
36
Fidelity Investments
Massachusetts
$825 -$4.84K -1,636 -84%
Barclays
37
Barclays
United Kingdom
$551 +$610 +206 +20,600%
AAP
38
Arax Advisory Partners
Colorado
$58 +$65 +22 New
LFG
39
Larson Financial Group
Missouri
$56 – – –
EWA
40
EverSource Wealth Advisors
Alabama
$45 -$41 -14 -45%
EP
41
Essential Partners
California
$43 -$50 -17 -52%
Citigroup
42
Citigroup
New York
$32 -$8.68K -2,931 -100%
Optiver Holding
43
Optiver Holding
Netherlands
$21 +$24 +8 New
TWD
44
True Wealth Design
Ohio
$8 -$12 -4 -57%
SS
45
Sunbelt Securities
Texas
$5 +$6 +2 New
SS
46
SBI Securities
Japan
$3 – – –
YIH
47
Y-Intercept (HK)
Hong Kong
– -$142K -47,885 Closed
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
– -$117K -39,381 Closed
JG
49
Jain Global
New York
– -$52.4K -17,629 Closed
HSBC Holdings
50
HSBC Holdings
United Kingdom
– -$48.7K -16,921 Closed
1
2
3

XBIT Hedge Fund Activity: Q3 2025 in Review

48 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2025, worth a combined $7.81M — down 23% from $10.1M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of XBIT and 4 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 11 added.

The largest buyer was Morgan Stanley, adding an estimated $106K. The largest seller was Millennium Management, cutting an estimated $400K.

  • 48 institutional investors held XBiotech (XBIT) as of Q3 2025, down from 53 in Q2 2025.
  • Funds reported $7.81M of XBiotech stock for Q3 2025, down 23% quarter-over-quarter.
  • 4 funds opened new XBiotech positions in Q3 2025 and 9 closed out, a net change of -5 holders.
  • The largest XBiotech buyer in Q3 2025 was Morgan Stanley, an estimated $106K added.
  • The largest XBiotech seller in Q3 2025 was Millennium Management, an estimated $400K sold.

Based on aggregated 13F filings for Q3 2025.